IWC
ANTX icon

Integrated Wealth Concepts’s AN2 Therapeutics ANTX Stock Holding History

Integrated Wealth Concepts’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$26.5K – 1978
2025
Q2 		$26.5K Hold
25,000
– – ﹤0.01% 1880
2025
Q1 		$34K Hold
25,000
– – ﹤0.01% 1711
2024
Q4 		$34.5K Hold
25,000
– – ﹤0.01% 1697
2024
Q3 		$26.8K Buy
+25,000
New +$43.4K ﹤0.01% 1658
2023
Q3 		– Sell
-12,500
Closed -$106K – 1560
2023
Q2 		$106K Buy
+12,500
New +$89.9K ﹤0.01% 1487

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integrated Wealth Concepts's ANTX Position: Q3 2025 in Review

Integrated Wealth Concepts sold out of AN2 Therapeutics (ANTX) in Q3 2025, closing a stake of 25,000 shares — an estimated $26.5K sold.

Integrated Wealth Concepts first reported a position in ANTX in Q2 2023 and held it in 5 quarters. The position peaked at $106K in Q2 2023. 35 funds tracked by Wall St. Rank hold ANTX as of Q3 2025.

  • Integrated Wealth Concepts reported no remaining AN2 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Integrated Wealth Concepts sold 25,000 AN2 Therapeutics shares in Q3 2025, an estimated $26.5K.
  • Integrated Wealth Concepts first reported a position in AN2 Therapeutics in Q2 2023 and held it in 5 quarters.
  • Integrated Wealth Concepts's AN2 Therapeutics position peaked at $106K in Q2 2023.
  • 35 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2025.

Based on Integrated Wealth Concepts's 13F filing for Q3 2025, filed 14 Nov 2025.